2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1433

Clinical Characterization of Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 1114

Clinical Effectiveness of Exercise and Corticosteroid Injection for Subacromial Impingement Syndrome: A Randomised Controlled Trial
Abstract Number: 1488

Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
Abstract Number: 1098

Clinical Efficacy of the High-Concentration Capsaicin Patch for the Treatment of Carpal Tunnel Syndrome
Abstract Number: 1907

Clinical Evaluation of Anti-Aminoacyl tRNA Synthase Antibodies in Rheumatoid Arthritis Patients
Abstract Number: 2653

Clinical Features in Patients with Anti-Triosephosphate Isomerase Antibody-Positive Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2303

Clinical Observation on Ankylosing Spondylitis Patients with Different Phenotypes
Abstract Number: 2911

Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?
Abstract Number: 2248

Clinical Outcomes, Neuropathic Pain and Patient Satisfaction over a 15 Year Period Following Primary Tka: A Repeat-Cross-Sectional Analysis
Abstract Number: 2700

Clinical Phenotype of Systemic Sclerosis Patients with Anti-RNA Polymerase III Antibodies: A New French Cohort, Systematic Review and Meta-Analysis
Abstract Number: 1225

Clinical Presentation and Cytokine Production Abnormalities in a Cohort of Patients Carrying NLRP12 GENE Variants
Abstract Number: 562

Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy
Abstract Number: 1557

Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody
Abstract Number: 309

Clinical Significance of Cytokine Profile with Interleukin-18 and -6 in Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2885

Clinical Training Opportunities in Two Innovative Ambulatory Resources: The Primary Care Musculoskeletal Clinic and Center of Excellence Multidisciplinary Clinic

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].